BioInvent Highlights BI-1206 NHL Combination Data at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced that new clinical findings from its ongoing Phase 1/2...
Hematology
Advertisement
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Ascentage Pharma Highlights Hematology Pipeline at EHA
ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 Ascentage Pharma announced that 17 major clinical advances across its hematology...
Enliven Therapeutics Reports Strong ELVN-001 CML Data
BOULDER, Colo., May 12, 2026 Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Advertisements
Incyte Corporation Wins FDA Approval for Jakafi XR
WILMINGTON, Del., May 1, 2026 Incyte Corporation has secured U.S. Food and Drug Administration (FDA) approval for Jakafi XR™...
Columvi Combo Doubles Survival in Three-Year STARGLO Results
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
Five-Year REZLIDHIA Data Reinforces Long-Term AML Outcomes
Dateline IntroductionNovember 18, 2025 — South San Francisco, CA — Rigel Pharmaceuticals has published final five-year clinical data on...
BioNTech Advances Oncology Pipeline and Strengthens 2025 Financial Outlook
MAINZ, Germany, November 3, 2025 — BioNTech SE (Nasdaq: BNTX) reported its third quarter 2025 financial results, highlighting significant...
Aptose to Present Promising Tuspetinib AML Data at 2025 ASH Meeting
SAN DIEGO and TORONTO, November 3, 2025 — Aptose Biosciences Inc. (TSX: APS), a clinical-stage precision oncology company, announced...
Advertisement
